Regulation of Endothelial Cell Cyclic Nucleotide Metabolism by Prostacyclin

Overview

Journal J Clin Invest

Specialty General Medicine

Date 1981 Feb 1

PMID 6257764

Citations 27

Authors

N K Hopkins

R R Gorman

Affiliations

Soon will be listed here.

Abstract

An analysis of prostaglandin-stimulated adenosine 3',5'-cyclic monophosphate (cyclic AMP) accumulation in cultured human umbilical vein endothelial cells showed prostacyclin (PGI2) to be the most potent agonist followed by prostaglandin (PG)H2, which was more potent than PGE2, while PGD2 was essentially inactive. The endothelial cells studied apparently have a high rate of cyclic AMP phosphodiesterase activity because significant PGI2-mediated increases in cyclic AMP could not be shown in the presence of the phosphodiesterase inhibitor isobutylmethylxanthine (MIX). Endoperoxide PGH2-stimulation of cyclic AMP accumulation was inhibited 75--80% by the prostacyclin synthetase inhibitors 12-hydroperoxyeicosatetraenoic acid or 9,11-azoprosta-5,13-dienoic acid. These data indicate that the PGH2-stimulation is due primarily to conversion to PGI2. The beta-adrenergic agonist L-isoproterenol stimulated cyclic AMP accumulation in the endothelial cells. This accumulation was completely blocked by propranolol. However, stimulation of cyclic AMP accumulation by the beta-adrenergic agent did not equal that induced by PGI2. Furthermore, the PGI2 response could not be blocked by propranolol. Thrombin-stimulated PGI2 biosynthesis was attenuated by PGE1 or isoproterenol in the presence of MIX. MIX alone was less effective than a combination of PGE1 or isoproterenol plus MIX. These data suggest two potential effects of PGI2 biosynthesis by endothelial cells: first, the PGI2 can elevate cyclic AMP in platelets, and second, endothelial cell cyclic AMP can be elevated as well, so that subsequent PGI2 synthesis will be attenuated.

Citing Articles

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in Human Lung Microvascular Endothelial Cells Controls Oxidative Stress, Reactive Oxygen-Mediated Cell Signaling and Inflammatory Responses.

Khalaf M, Scott-Ward T, Causer A, Saynor Z, Shepherd A, Gorecki D Front Physiol. 2020; 11:879.

PMID: 32848840 PMC: 7403513. DOI: 10.3389/fphys.2020.00879.

Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells.

Campos-Toimil M, Keravis T, Orallo F, Takeda K, Lugnier C Br J Pharmacol. 2008; 154(1):82-92.

PMID: 18311187 PMC: 2438981. DOI: 10.1038/bjp.2008.56.

Inhibition of the production of endothelium-derived hyperpolarizing factor by cannabinoid receptor agonists.

Fleming I, Schermer B, Popp R, Busse R Br J Pharmacol. 1999; 126(4):949-60.

PMID: 10193775 PMC: 1571212. DOI: 10.1038/sj.bjp.0702381.

The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3', 5'-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats.

Siragy H, Carey R J Clin Invest. 1996; 97(8):1978-82.

PMID: 8621783 PMC: 507268. DOI: 10.1172/JCI118630.

Myocardial adenosine stimulates release of cyclic adenosine monophosphate from capillary endothelial cells in guinea pig heart.

Kroll K, Schrader J Pflugers Arch. 1993; 423(3-4):330-7.

PMID: 8391684 DOI: 10.1007/BF00374413.

References

Hamberg M, Svensson J, Samuelsson B . Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins. Proc Natl Acad Sci U S A. 1974; 71(10):3824-8. PMC: 434276. DOI: 10.1073/pnas.71.10.3824. View

Marcus A, Weksler B, Jaffe E . Enzymatic conversion of prostaglandin endoperoxide H2 and arachidonic acid to prostacyclin by cultured human endothelial cells. J Biol Chem. 1978; 253(20):7138-41. View

Harper J, Brooker G . Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2'0 acetylation by acetic anhydride in aqueous solution. J Cyclic Nucleotide Res. 1975; 1(4):207-18. View

Gorman R, Bunting S, MILLER O . Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins. 1977; 13(3):377-88. DOI: 10.1016/0090-6980(77)90018-1. View

Tateson J, Moncada S, Vane J . Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins. 1977; 13(3):389-97. DOI: 10.1016/0090-6980(77)90019-3. View

Gorman R, Sun F, MILLER O, Johnson R . Prostaglandins H1 and H2. Convenient biochemical synthesis and isolation. Further biological and spectroscopic characterization. Prostaglandins. 1977; 13(6):1043-53. DOI: 10.1016/0090-6980(77)90132-0. View

Weksler B, Ley C, Jaffe E . Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A 23187. J Clin Invest. 1978; 62(5):923-30. PMC: 371849. DOI: 10.1172/JCI109220. View

Gorman R, HAMILTON R, Hopkins N . Stimulation of human foreskin fibroblast adenosine 3':5'-cyclic monophosphate levels by prostacyclin (prostaglandin I2). J Biol Chem. 1979; 254(5):1671-6. View

Kather H, Simon B . Effects of some naturally occurring prostaglandins of the D-, E-, and I-type and synthetic analogues on adenylate cyclase of human fat cell ghosts. Res Exp Med (Berl). 1979; 176(1):25-9. DOI: 10.1007/BF01852108. View

10.

MILLER O, Aiken J, Hemker D, Shebuski R, Gorman R . Prostacyclin stimulation of dog arterial cyclic AMP levels. Prostaglandins. 1979; 18(6):915-25. DOI: 10.1016/0090-6980(79)90128-x. View

11.

Dray F, Gerozissis K, Kouznetzova B, Mamas S, Pradelles P, Trugnan G . New approach to the RIA of prostaglandins and related compounds using iodinated tracers. Adv Prostaglandin Thromboxane Res. 1980; 6:167-80. View

12.

MILLER O, Aiken J, Shebuski R, Gorman R . 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent. Prostaglandins. 1980; 20(2):391-400. DOI: 10.1016/s0090-6980(80)80056-6. View

13.

LOWRY O, ROSEBROUGH N, FARR A, RANDALL R . Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1):265-75. View

14.

Weibel E, Palade G . NEW CYTOPLASMIC COMPONENTS IN ARTERIAL ENDOTHELIA. J Cell Biol. 1964; 23:101-12. PMC: 2106503. DOI: 10.1083/jcb.23.1.101. View

15.

Rodbell M . Metabolism of isolated fat cells. V. Preparation of "ghosts" and their properties; adenyl cyclase and other enzymes. J Biol Chem. 1967; 242(24):5744-50. View

16.

Steiner A, Parker C, KIPNIS D . Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. J Biol Chem. 1972; 247(4):1106-13. View

17.

Jaffe E, Nachman R, Becker C, Minick C . Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973; 52(11):2745-56. PMC: 302542. DOI: 10.1172/JCI107470. View

18.

Buonassisi V, Venter J . Hormone and neurotransmitter receptors in an established vascular endothelial cell line. Proc Natl Acad Sci U S A. 1976; 73(5):1612-6. PMC: 430349. DOI: 10.1073/pnas.73.5.1612. View

19.

Moncada S, Higgs E, Vane J . Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet. 1977; 1(8001):18-20. DOI: 10.1016/s0140-6736(77)91655-5. View

20.

WHITTAKER N, Bunting S, Salmon J, Moncada S, Vane J, Johnson R . The chemical structure of prostaglandin X (prostacyclin). Prostaglandins. 1976; 12(6):915-28. DOI: 10.1016/0090-6980(76)90126-x. View